Skip to main content

Table 3 Tumor response

From: Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study

Variable Total (n = 38)
Best response, n (%)
Complete response 1 (2.6)
Partial response 2 (5.3)
Stable disease 26 (68.4)
Progressive disease 9 (23.7)
Objective response rate, n (%) 3 (7.9)
Disease control rate, n (%) 29 (76.3)
6-month PFS rate, % (95% CI) 59.8 (41.8, 77.8)